Brian M. Wolpin
Harvard University
Genome-wide association studyCancerInternal medicineEndocrinologySurgeryOncologySingle-nucleotide polymorphismOdds ratioProspective cohort studyHazard ratioDiseasePancreatic cancerAdenocarcinomaPopulationCancer researchColorectal cancerGeneticsMedicineBiologyGastroenterology
294Publications
64H-index
11.6kCitations
Publications 283
Newest
#1Andrew Eugene Hendifar (Cedars-Sinai Medical Center)H-Index: 28
#2Edik M. BlaisH-Index: 11
Last. Samuel J. Klempner (Harvard University)H-Index: 28
view all 0 authors...
PURPOSEIn pancreatic cancer (PC), the RAF family alterations define a rare subset of patients that may predict response to inhibition of the BRAF/MEK/ERK signaling pathway. A comprehensive understa...
Source
#1Harshabad Singh (Harvard University)H-Index: 9
#2Kimberly Perez (Harvard University)H-Index: 12
Last. Andrew J. Aguirre (Harvard University)H-Index: 26
view all 4 authors...
Source
Source
#1Yin Zhang (Harvard University)H-Index: 5
#2Mingyang SongH-Index: 46
Last. Walter C. Willett (Harvard University)H-Index: 385
view all 13 authors...
Background null Unrestrained eating behavior, as a potential proxy for diet frequency, timing, and caloric intake, has been questioned as a plausible risk factor for digestive system cancers, but epidemiological evidence remains sparse. null Objectives null We investigated prospectively the associations between unrestrained eating behavior and digestive system cancer risk. null Methods null Participants in the Nurses' Health Study who were free of cancer and reported dietary information in 1994 ...
Source
#1James M. Cleary (Harvard University)H-Index: 33
#2Brian M. Wolpin (Harvard University)H-Index: 64
Last. Andrew J. Aguirre (Harvard University)H-Index: 26
view all 11 authors...
Pancreatic cancer is rapidly progressive and notoriously difficult to treat with cytotoxic chemotherapy and targeted agents. Recent demonstration of the efficacy of maintenance PARP inhibition in germline BRCA mutated pancreatic cancer has raised hopes that increased understanding of the DNA damage response pathway will lead to new therapies in both homologous recombination (HR) repair-deficient and proficient pancreatic cancer. Here, we review the potential mechanisms of exploiting HR deficienc...
Source
Last. Mengmeng Du (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
view all 79 authors...
Background null Epidemiological studies have suggested positive associations for iron and red meat intake with risk of pancreatic ductal adenocarcinoma (PDAC). Inherited pathogenic variants in genes involved in the hepcidin-regulating iron metabolism pathway are known to cause iron overload and hemochromatosis. null Objectives null The objective of this study was to determine whether common genetic variation in the hepcidin-regulating iron metabolism pathway is associated with PDAC. null Methods...
Source
#1Hongjie Chen (UW: University of Washington)
#3Lu Wang (UW: University of Washington)
Last. Helian Feng (Harvard University)
view all 59 authors...
Abstract null null Genome-wide association studies (GWAS) have identified thousands of cancer risk loci revealing many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic basis can increase our understanding of global mechanisms of cancer development. In this study, we collected GWAS summary statistics based on up to 375,468 cancer cases and 530,521 controls for fourteen types of cancer, including breast (overall, estrogen receptor (ER)-positive and ER-neg...
Source
#1Jasper E. NeggersH-Index: 8
#2Brenton R. PaolellaH-Index: 11
Last. Jeremie KalfonH-Index: 4
view all 27 authors...
Source
#1Xiao LuoH-Index: 2
#2Wanshui YangH-Index: 10
Last. Chun-Han LoH-Index: 8
view all 16 authors...
Source
#1Katelyn T. Byrne (UPenn: University of Pennsylvania)H-Index: 18
#2Courtney B. Betts (OHSU: Oregon Health & Science University)H-Index: 12
Last. Craig Newcomb (UPenn: University of Pennsylvania)H-Index: 32
view all 29 authors...
Deploying CD40 activation to stimulate T cell responses upstream of immune checkpoint molecules is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological treatment effects especially treatment-related modulation of the tumor microenvironment (TME), remain poorly understood. Here, we performed a neoadjuvant clinical trial of agonistic CD40 mAb (selicrelumab) administered intravenously with or witho...
Source